Knight Therapeutics, Inc. · TSX:GUD

Knight Therapeutics — Q3 2026 Earnings Presentation

21 slides from Knight Therapeutics's earnings presentation, November 2026

  1. Slide 1: Transforming Lives, Delivering Results

    TRANSFORMING LIVES DELIVERING RESULTS KNIGHT THERAPEUTICS INC. TSX: GUD NOVEMBER 2026

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This document contains forward-looking statements and forward-looking information for Knight Therapeutics Inc. and its subsidiaries within the meaning of applicable Canadian securities laws. Forward-looking statements are subject to known and unknown risks, uncertainties a

  3. Slide 3: Knight Overview

    Knight Overview Building a Solid Foundation Since 2014 Commercial Stage Pharmaceutical Company Focused on Acquiring and In-Licensing Innovative Pharmaceutical Products for Canada and Latin America $685M 2019 June 2025 Acquisition of Grupo Biotoscana, Closed Paladin and Raised in equity a Latin Ameri

  4. Slide 4: Scaling the Platform

    Scaling the Platform By the Numbers $562M $101M $137M Adjusted Revenue in TTM Q3-2026 Adjusted EBITDA in TTM Q3-2026 Cash and Marketable Securities 36% Growth vs. TTM Q3-2025 58% Growth vs. TTM Q3-2025 $115M Net cash 17 agreements $300M+ $280M signed for 65+ products Pipeline and Launched Pipeline S

  5. Slide 5: Our Growth Strategies

    Our Growth Strategies Knight’s Involvement Regulatory Sales & Discovery Pre-Clinical Clinical Trials Market Access Approval Marketing 2 - 10 yrs 2 - 4 yrs 5 - 7 yrs 1 - 3 yrs 1 - 3 yrs 3 - 5 yrs 1 In-license late-stage prescription pharmaceuticals 2 Acquire mature or “under-promoted” products from B

  6. Slide 6: Our Footprint

    Our Footprint Growing Across Key Markets ADJUSTED REVENUE BY GEOGRAPHY $562M 11 Countries Other Adjusted Revenue plus distributors in Central Mexico 4% TTM Q3-2026 America & Caribbean 5% Argentina 9% Brazil 36% Rest of LATAM 7% TTM Q3-2026 850+ 150+ Products Employees 25+ Pipeline & early launch pro

  7. Slide 7: Our Markets – Sizable & Growing

    Our Markets – Sizable & Growing Pan-American (ex US) represents ~7% of global pharma market MARKET SIZE AT CONSTANT CURRENCY1 $120 $100 $80 Larger market allows Knight to $ BILLIONS $60 112.2 104.6 access more licensing $40 77.7 87.3 93.9 and acquisition opportunities. 48.4 51.9 43.6 44.3 48.2 $20 3

  8. Slide 8: Our Portfolio

    Our Portfolio Built for Stability and Growth ADJUSTED REVENUE KEY PRODUCTS BY THERAPEUTIC AREA BY PRODUCT Discontinued Promoted - Launched Oncology & Hematology PORTFOLIO Pipeline Products 1% 12% Mature 35% $562M TTM Q3-2026 Promoted - Infectious Diseases Strategic Products 52% BY THERAPEUTIC AREA O

  9. Slide 9: Our Partners

    Our Partners Partner of Choice for Canada & Latin America *The above registered trademarks, or logos, are owned by Knight’s partners. For example: Incyte and the Incyte logo are registered trademarks of Incyte. 9

  10. Slide 10: Financial Highlights: Revenue Growing in all Therapeutic Areas

    Financial Highlights Revenue Growing in all Therapeutic Areas ADJUSTED REVENUE BY THERAPEUTIC AREA $600 $550 $500 $450 $400 2026 Revenue Guidance $350 C$ MILLIONS $300 Between $560 - $570M $250 $200 $150 (>24% growth $100 over 2025) $50 $0 2019 2020 2021 2022 2023 2024 2025 TTM Q3-26 Oncology & Hema

  11. Slide 11: Financial Highlights: Strong Adjusted EBITDA and Cash Flow

    Financial Highlights Strong Adjusted EBITDA and Cash Flow ADJUSTED EBITDA CASH FLOW FROM OPERATIONS $120 $140 $120 $100 $100 $80 $80 C$ MILLIONS C$ MILLIONS $60 $60 $40 $40 $20 $20 $0 $0 -$20 2019 2020 2021 2022 2023 2024 2025 TTM Q3- 2019 2020 2021 2022 2023 2024 2025 TTM Q3- 2026 2026 2026 Adjuste

  12. Slide 12: Balance Sheet Highlights (September 30, 2026)

    Balance Sheet Highlights (September 30, 2026) Healthy Balance Sheet with Capacity for More Acquisitions $137M $77M $22M Cash and Marketable Securities Financial Assets Debt $1.39/share $0.78/share $0.23/share 0.22 x 0.03:1 Credit Available1 Debt to TTM Debt to Equity Lines of Credit: $140M Adjusted

  13. Slide 13: Capital Allocation

    Capital Allocation Executing on Acquisitions and NCIB PRODUCTS & ACQUISITIONS SHARE BUYBACK $250 $70 $60 $200 $50 $150 $40 C$ MILLIONS C$ MILLIONS $30 $100 $20 $50 $10 $0 $0 2019 2020 2021 2022 2023 2024 2025 TTM Q3 2019 2020 2021 2022 2023 2024 2025 TTM Q3 2026 2026 Over $260M invested in NCIB Biot

  14. Slide 14: Capital Structure

    Capital Structure As at November 5, 2026 ~$1.1B 98.3M 23.4% Market Capitalization Common Shares Outstanding Insider Holdings % ~$945M $101M 7.3M Adjusted Enterprise Value Adjusted EBITDA in TTM Q3-2026 Stock Options and Share Awards Refer to the Footnotes & Glossary slide for definitions of non-IFRS

  15. Slide 15: Management Team

    Management Team Executing on Growth & Performance Monica Percario - Brazil Global VP Regulatory and Quality Samira Sakhia - Canada Sanofi, Head of Regulatory and Center of Expertise LATAM President and Chief Executive Officer Farmasa (now Hypera Pharma), Regulatory Affairs Paladin Labs, Chief Financ

  16. Slide 16: Board Members

    Board Members Proven Track Record Jonathan Ross Goodman Robert N. Lande Executive Chairman Paladin Labs, Board member from 1995 to 2014 Knight Therapeutics, Founder Stratos Global International LLC, President Paladin Labs, Co-founder, former President & CEO Michael J. Tremblay Former President of As

  17. Slide 17: Knight’s Future Growth

    Knight’s Future Growth Keep Growing, Keep Adding Add new Grow products to existing the products portfolio Deliver on new launches and pipeline 17

  18. Slide 18: Key Achievements – since January 2024

    Key Achievements – since January 2024 Going from Pipeline to Growth 50+ New Products • Added Paladin assets – 40+ products • Added Sumitomo assets – 6 products • Crexont® • Onicit® Launches • Three branded generic products • Minjuvi® - DLBCL • Zynyz® • Minjuvi® - FL • Niktimvo® • Imvexxy® & Bijuva®

  19. Slide 19: A Proven Business Model

    A Proven Business Model Focused on Delivering Results Proven Scaled Platform Strong Investment Foundation Clear Path Forward ► Canada & Latin America footprint ► Disciplined capital allocation ► Deliver launches & pipeline ► Proven record to build portfolio ► Strong balance sheet ► Expand product po

  20. Slide 20: Footnotes & Glossary

    Footnotes & Glossary (1) Adjusted Revenue, Adjusted EBITDA, and Adjusted EBITDA per share are non-IFRS measures and do not have any standardized meaning under IFRS. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to Financial Resul

  21. Slide 21: Transforming Lives, Delivering Results

    TRANSFORMING LIVES DELIVERING RESULTS KNIGHT THERAPEUTICS INC. TSX: GUD NOVEMBER 2026

Knight Therapeutics — Q3 2026 Earnings Presentation on 6ix